Personalis’s liquid biopsy is part of a growing market for minimal residual disease assays, tests that look for any remaining cancer cells after the initial treatment. Tempus AI has been the commercial partner on this Personalis test since 2023.
The post Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis appeared first on MedCity News.
